← All trials
NCT05979207
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2023
- Primary completion
- Oct 30, 2023
- Completion date
- Oct 30, 2023
- First posted
- Aug 7, 2023
- Last posted
- Sep 5, 2023
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medicines for Malaria VentureLead sponsor
- GlaxoSmithKlineCollaborator
- ICONCollaborator
- Medicines for Malaria VentureStudy director
- University of QueenslandCollaborator
- Southern Star Research Pty Ltd.Collaborator
- Swiss BioQuant A.G., SwitzerlandCollaborator
- Sunshine Coast University, AustraliaCollaborator
- Medicines for Malaria VentureOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.